- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07951138
A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Three-Period, Six-Sequence Crossover Study in Healthy Volunteers to Compare the Relative Bioavailability of Itraconazole Tablet (T26) and Itraconazole Capsule (Sporanox®) Under Fed Conditions and to Assess the Food Effect on T26
This is a phase 1, randomized, open-label, single-center, single-dose, three-period, six-sequence crossover study in healthy adult volunteers. The study is designed to compare the relative bioavailability of itraconazole tablet (T26, Test) with itraconazole capsule (Sporanox®, Reference) under fed conditions; and to assess the food effect from a high-fat meal on T26.
Three treatments, as described below, are planned:
Test Product (Tfed): T26, 130 mg (two 65 mg tablets), administered under fed conditions Reference Product (R): Sporanox®, 200 mg (two 100 mg capsules), administered under fed conditions Test Product (Tfasted): T26, 130 mg (two 65 mg tablets), administered under fasted conditions A total of 18 participants will be randomized 1:1:1:1:1:1 into six different treatment sequences (TfastTfedR, TfastRTfed, TfedTfastR, TfedRTfast, RTfastTfed, RTfedTfast). The dosing between two consecutive treatment periods will be separated by a minimum 14-day washout interval.
This study consists of three periods: a screening period (Day -7~Day -2), a cross-over treatment period, and a safety follow-up visit (Day 36 ~Day 43). During each treatment period, eligible participants will be admitted to the clinical research unit (CRU) one day prior to dosing and will receive a single oral dose of the assigned study treatment on Day 1 according to the randomized sequence. On Day 1 of each treatment period, T26 or Sporanox® will be administered with 240 mL of water at approximately 8:00 a.m. (±1 hour) under fasted or fed condition. Detailed dietary requirements and dosing procedures. Participants will discharge from the CRU on the fifth day of each treatment period after completion of the scheduled safety assessments and collection of the last PK blood sample (up to 96 hours post-dose).
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Junya Yu
- Numero di telefono: 18752010068
- Email: yujunya@triastek.com
Luoghi di studio
-
-
NA, Municipality
-
Chongqing, NA, Municipality, Cina, 400020
- No. 1, Jialing Yicun, Liangjiang New Area, Chongqing
-
Contatto:
- Liangying Liu
- Numero di telefono: +86-13436012840
- Email: 37145266@qq.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Healthy male and female participants aged 18 years and above (including 18 years).
-
Male participants with body weight ≥50.0 kg and female participants with body weight ≥45.0 kg. Body Mass Index (BMI) = weight (kg) / height² (m²), within the range of 18.5-30.0 kg/m² (inclusive).
-
Participants with no history of chronic or serious diseases of the cardiovascular, digestive, urinary, respiratory, hematologic/lymphatic, endocrine, immune, psychiatric, or nervous systems, and in good general health.
-
Participants must be willing to use effective contraception from screening until 2 months after the last dose of the final treatment cycle.
a) Female participants must: i. Be of non-child-bearing potential i.e. surgically sterilized or postmenopausal, or ii. If of child-bearing potential, must have a negative pregnancy test at Screening and within 24 hours prior to treatment Day 1. They must agree not to attempt to become pregnant, must not donate ova, and must agree to use two forms of highly effective contraceptive method between signing consent, during the study, and at least 2 months after the last dose of study drug, OR use 1 form of highly effective contraceptive method, plus an additional barrier method of contraception between signing consent, during the study, and at least 2 months after the last dose of study drug.
iii. Women of childbearing potential (WCBP) with same sex partners who abstain from penile- vaginal intercourse are eligible if such is their preferred and usual lifestyle.
c) Male participants must: i. Be willing not to donate sperm until at least 2 months after the last dose of study drug and.
ii. If engaging in sexual intercourse with a female partner who could become pregnant, be willing to use a condom in addition to having the female partner use a highly effective contraceptive method between signing consent, during the study, and at least 2 months after the last dose of study drug.
-
Voluntarily sign an informed consent form prior to the trial, with full understanding of the trial content, procedures, and potential adverse reactions, and be able to communicate effectively with investigators.
-
Capable of completing the study in accordance with the trial protocol requirements.
Exclusion Criteria:
- Vital signs, physical examination, hearing assessment, laboratory tests (hematology, urinalysis, blood chemistry, coagulation panel), infectious disease panel, 12-lead ECG, etc., showing clinically significant abnormalities;
- (Inquiry) Smoking 5 or more cigarettes per day on average within 3 months prior to screening, or unable to refrain from using any tobacco product within 48 h prior to administration and during hospitalization;
- (Inquiry) History of acute infectious disease with significant antibiotic use within 3 months before screening, or mild infectious disease within 7 days before first dose;
- (Inquiry) History of allergy to itraconazole, other azoles, or any excipients of the investigational product, or allergy to two or more substances;
- (Inquiry) Alcohol consumption >14 units per week within 3 months before screening (1 unit = 17.7 mL ethanol, equivalent to ~354 mL of 5% beer, ~44 mL of 40% spirits, or ~147 mL of 12% wine), or unable to abstain from alcohol-containing products during the study, or positive alcohol breath test;
- (Inquiry) Received blood transfusion, donated blood, or experienced major blood loss (≥400 mL) within 3 months before first dose;
- (Inquiry) Vaccinated within 14 days before first dose, or planning vaccination during the study period;
- (Inquiry) Taken any prescription medication, over-the-counter medication, vitamin products, or herbal supplements within 2 weeks before first dose;
- (Inquiry) Participants who, within 72 hours prior to the first dose, have consumed special diet (including dragon fruit, mango, grapefruit, etc.), or consumed foods or beverages containing caffeine or rich in xanthine (such as chocolate, strong tea, coffee, cola, animal offal), engaged in vigorous exercise, or have other factors affecting drug absorption, distribution, metabolism, or excretion;
- (Inquiry + System Search) Used other investigational products or participated in clinical drug trials within 3 months before first dose;
- Experienced acute illness or required concomitant medication from screening until first dose;
- Female participants who are breastfeeding or have a positive pregnancy test results at screening or during the study period;
- History of drug abuse within the past year, or illicit drug use within 3 months before screening, or positive drug abuse screening test;
- (Inquiry) Dysphagia, lactose intolerance (e.g., history of diarrhea after milk consumption), or inability to comply with standardized diet;
- (Inquiry) History of diseases that may affect safety or pharmacokinetics of the investigational product, such as gastric spasms, gastroesophageal reflux disease, Crohn's disease, chronic atrophic gastritis, Sjögren's syndrome, pernicious anemia, etc., or currently having any of these conditions;
- (Inquiry) Post-partial gastrectomy, or major surgery within 6 months before screening, or planning surgery during the study, or history of surgery affecting drug absorption, distribution, metabolism, or excretion (except appendectomy);
- (Inquiry + System Search) History of serious conditions judged by the investigator as clinically significant in the cardiovascular system (including congestive heart failure, coronary atherosclerotic heart disease, valvular heart disease, arrhythmia, torsades de pointes), hepatic system (active liver disease), urinary system, digestive system, respiratory system (including chronic obstructive pulmonary disease, cystic fibrosis), hematologic/lymphatic system (e.g., neutropenia), nervous system, psychiatric system, visual disorders/abnormalities, auditory disorders (including tinnitus and sudden deafness), malignant tumors, or currently having any of these conditions;
- (Inquiry) Use of any drugs known to interact with itraconazole within 4 weeks before screening [including methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (e.g., dihydroergotamine, ergometrine, ergotamine, methylergometrine), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, levacetylmethadol (levomethadyl), halofantrine, astemizole, mizolastine, terfenadine, sertindole, bepridil, lercanidipine, ivabradine, domperidone, colchicine, fesoterodine, telithromycin, solifenacin, erythromycin, clarithromycin, etc.];
- (Inquiry) Female participants who have used long-acting estrogen or progestogen injections or implants within 6 months before the study, or short-acting contraceptives within 30 days before the study;
- (Inquiry) History of vasovagal syncope from blood or needles, or unable to tolerate venipuncture;
- Participants unable to complete the study due to other reasons;
- Participants judged by the investigator to have other factors unsuitable for participation in this study;
- Participants with creatinine clearance <80 mL/min (calculated using Cockcroft-Gault formula: CrCl = [(140 - age) × weight (kg)] / [0.818 × serum creatinine (μmol/L)]; for females, multiply result by 0.85);
- (Inquiry) Participants with decreased gastric acidity, such as participants taking gastric acid secretion suppressors (e.g., H₂-receptor antagonists, proton pump inhibitors) or participants with achlorhydria caused by certain diseases.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Tfasted-Tfed-R group
|
Test Product Reference Product |
|
Sperimentale: Tfasted-R-Tfed group
|
Test Product Reference Product |
|
Sperimentale: Tfed-Tfasted-R group
|
Test Product Reference Product |
|
Sperimentale: Tfed-R-Tfasted group
|
Test Product Reference Product |
|
Sperimentale: R-Tfasted-Tfed group
|
Test Product Reference Product |
|
Sperimentale: R-Tfed-Tfasted group
|
Test Product Reference Product |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Cmax
Lasso di tempo: up to 96 hours post-dose
|
Primary PK parameters |
up to 96 hours post-dose
|
|
AUC0-tlast
Lasso di tempo: up to 96 hours post-dose
|
Primary PK parameters |
up to 96 hours post-dose
|
|
AUC0-inf
Lasso di tempo: up to 96 hours post-dose
|
Primary PK parameters |
up to 96 hours post-dose
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Tmax
Lasso di tempo: up to 96 hours post-dose
|
Secondary PK parameters |
up to 96 hours post-dose
|
|
t₁/₂
Lasso di tempo: up to 96 hours post-dose
|
Secondary PK parameters |
up to 96 hours post-dose
|
|
Kel
Lasso di tempo: up to 96 hours post-dose
|
Secondary PK parameters |
up to 96 hours post-dose
|
|
F
Lasso di tempo: up to 96 hours post-dose
|
Secondary PK parameters |
up to 96 hours post-dose
|
|
CL/F
Lasso di tempo: up to 96 hours post-dose
|
Secondary PK parameters |
up to 96 hours post-dose
|
|
Vz/F
Lasso di tempo: up to 96 hours post-dose
|
Secondary PK parameters |
up to 96 hours post-dose
|
|
AUC_%Extrap
Lasso di tempo: up to 96 hours post-dose
|
Secondary PK parameters |
up to 96 hours post-dose
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- T26-101
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .